The invention concerns a novel compound – 5-selenocyanato-2’-deoxyuridine (SeCNdU) – its synthesis method and application for sensitizing the cancer cell genome to ionizing radiation. The compound acts as a DNA radiosensitizer, enhancing the sensitivity of tumor cells to radiotherapy.
Compared to the classical 5-bromo-2’-deoxyuridine (BrdU), SeCNdU shows a more favorable electron-induced degradation profile, leading to higher radiosensitizing efficiency under hypoxic conditions typical of solid tumors.
The compound was synthesized under controlled cryogenic conditions, and its activity was confirmed by both computational (DFT) and experimental studies.
Application:
- Radiosensitizer enhancing cancer therapy effectiveness,
- Potential component of oncology drugs supporting radiotherapy,
- Research tool in molecular biology and radiation chemistry.
